BACKROUND: Voriconazole is a novel triazole antifungal with a broad spectrum including
Aspergillus species. We conducted an open, noncomparative multicenter study to evaluate …

The risk of opportunistic infections is greatly increased in patients who are
immunocompromised due to AIDS, cancer chemotherapy and organ or bone marrow …

Invasive aspergillosis has been studied in laboratory by the means of plethora of distinct
animal models. They were developed to address pathophysiology, therapy, diagnosis, or …

Invasive fungal infections have emerged as important causes of morbidity and mortality in
profoundly immunocompromised patients with cancer. Current treatment strategies for these …

The first generation antifungal agent triazoles, fluconazole and itraconazole, have
revolutionised the treatment of serious fungal infections such as mucosal and invasive …

Voriconazole is a new triazole antifungal agent structurally related to fluconazole, but with
improved potency and spectrum of activity. Voriconazole has good in vitro activity against …

The new triazole antifungal, voriconazole (Vfend®, Pfizer Ltd), was developed for the
treatment of life-threatening fungal infections in immunocompromised patients. The drug …

This report describes a simple, rapid and reproducible method with a calibration range of 0.2–
10 μg ml− 1 voriconazole in human plasma which is more appropriate for routine clinical use …

Aspergillosis is an airborne fungal disease caused by Aspergillus spp., a group of
ubiquitous molds. This disease causes high morbidity and mortality in both humans and …

Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in
vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory …